| Literature DB >> 35489596 |
Kai Zhang1, Siddharth Karanth2, Bela Patel2, Robert Murphy3, Xiaoqian Jiang3.
Abstract
OBJECTIVE: The Coronavirus Disease 2019 (COVID-19) pandemic has overwhelmed the capacity of healthcare resources and posed a challenge for worldwide hospitals. The ability to distinguish potentially deteriorating patients from the rest helps facilitate reasonable allocation of medical resources, such as ventilators, hospital beds, and human resources. The real-time accurate prediction of a patient's risk scores could also help physicians to provide earlier respiratory support for the patient and reduce the risk of mortality.Entities:
Keywords: Deep neural network; Gaussian process; Mechanical ventilation prediction
Mesh:
Year: 2022 PMID: 35489596 PMCID: PMC9044651 DOI: 10.1016/j.jbi.2022.104079
Source DB: PubMed Journal: J Biomed Inform ISSN: 1532-0464 Impact factor: 8.000
Fig. 1MGP-MS model overview. The model combines a Multi-task Gaussian Process module with a self-attention neural network for trajectory prediction.
Lab tests, vital signs (observations) used in the experiment.
| Index | Lab tests | Index | Vitals and Observations |
|---|---|---|---|
| 1 | Blood urea nitrogen (BUN) | 1 | Diastolic Blood Pressure (DBP) |
| 2 | Phosphorus (PO4) | 2 | Heart Rate (HR) |
| 3 | Total serum bilirubin (TSB) | 3 | Systolic Blood Pressure (SBP) |
| 4 | Hematocrit (HCT) | 4 | Respiratory Rate (RESP) |
| 5 | Lactate Dehydrogenase (LDH) | 5 | Pulse Rate (PULSE) |
| 6 | Mean Corpuscular Volume (MCV) | 6 | Urine Output (UROUT) |
| 7 | Partial Thromboplastin Time (PTT) | 7 | Weight (WT) |
| 8 | Ferritin | 8 | Body Temperature |
| 9 | Conjugated (“directed”) Bilirubin | 9 | Pain Assessment |
| 10 | Total Calcium | ||
| 11 | Alkaline Phosphatase (ALP) | ||
| 12 | Alanine Aminotransferase (ALT) | ||
| 13 | Aspartate Aminotransferase (AST) | ||
| 14 | Mean Corpuscular Hemoglobin Concentration (MCHC) | ||
| 15 | Immature granulocytes/100 leukocytes in Blood by Automated count | ||
| 16 | Prothrombin Time (PT) |
Medicine administrations.
| Index | Medicine Class | Index | Medicine Class |
|---|---|---|---|
| 1 | Central nervous system agents | 10 | Nutritional agents |
| 2 | Respiratory agents | 11 | Hormones, synthetic substitutes, & metabolic agents |
| 3 | Anti-infective agents | 12 | Ophthalmic preparations |
| 4 | Cardiovascular agents | 13 | Skin & mucus membrane condition agents |
| 5 | Gastrointestinal agents | 14 | Biologic & immunologic agents |
| 6 | Antineoplastic agents | 15 | Mouth & throat preparations |
| 7 | Electrolyte, caloric, water balance agents | 16 | Otic preparations |
| 8 | Blood formation & coagulation agents | 17 | Compounding products |
| 9 | Medical supplies | 18 | Diagnostic agents |
| 10 | Miscellaneous agents |
Characteristics of the Study Sample (N = 9,532).
| Intubation | |
| Intubated | 1,485 (15.58%) |
| Not intubated | 8,047 (84.42%) |
| Mean age (range) | 65.12 (21.23, 89.10) |
| Gender | |
| Female | 4,231 (44.39%) |
| Male | 5,299 (55.59%) |
| Unknown | 2 (0.02%) |
| Race | |
| Caucasian | 5,155 (54.08%) |
| Other/Unknown | 1,803 (18.92%) |
| African American | 2,299 (24.12%) |
| Asian | 275 (2.89%) |
| Ethnicity | |
| Unknown | 1,036 (10.87%) |
| Not Hispanic | 7,287 (76.45%) |
| Hispanic | 1,209 (12.68%) |
| Region | |
| West | 492 (5.16%) |
| Northeast | 4,725 (49.57%) |
| Midwest | 3,532 (37.05%) |
| Other/Unknown | 246 (2.58%) |
| South | 537 (5.63%) |
| Deceased | |
| No | 7,473 (78.40%) |
| Yes | 2,059 (21.60%) |
Fig. 2Data completeness of lab tests and vital signs (100% means a feature's data is fully complete).
Fig. 3The average risk score trajectories of the two classes of patients with the shaded area denote the +/− 1 standard deviation. The right panel shows the two risk score distributions at the 64th hour, and the Wilcoxon rank-sum test yields a p-value of when assuming the null hypothesis to be two distributions are the same.
Fig. 4Two sample patients' risk score trajectory prediction using different models. (a) The risk score pathway of a randomly selected patient with COVID-19 who would need MV after 3 days since admission. (b) The risk score pathway of a randomly selected patient with COVID-19 who would not need MV after 3 days since admission.
Fig. 5Performance evaluation of different models, (a) Consistency (b) Robustness.
Fig. 6Scatter plots of 200 sample patients' trajectory robustness and slopes. (a) Logistic Regression, (b) XGBoost, (c) Cox Proportional-Hazard Model, (d) the proposed MGP-MS model.
AUROC and AUPRC Performance Comparison.
| Model | Admission | 0.5 Day | 1 Day | 2 Days | 3 Days | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| AUROC | AUPR | AUROC | AUPR | AUROC | AUPR | AUROC | AUPR | AUROC | AUPR | |
| GRU-ffill | 0.7378 | 0.3193 | 0.7404 | 0.3348 | 0.7901 | 0.3756 | 0.7754 | 0.4048 | 0.8061 | 0.4447 |
| GRU-D | 0.6080 | 0.2420 | 0.6062 | 0.2442 | 0.6747 | 0.3031 | 0.7517 | 0.4109 | 0.8099 | |
| MGP-TCN | 0.5972 | 0.2220 | 0.5862 | 0.2135 | 0.6394 | 0.3131 | 0.7602 | 0.3909 | 0.7732 | 0.4632 |
| IPN | 0.7034 | 0.3473 | 0.7286 | 0.3687 | 0.7605 | 0.3904 | 0.7653 | 0.4116 | 0.7770 | 0.4014 |
| T-LSTM | 0.5051 | 0.1836 | 0.5132 | 0.2020 | 0.5540 | 0.2642 | 0.6140 | 0.3525 | 0.6910 | 0.3956 |
| MGP-GRU | 0.7048 | 0.2912 | 0.7329 | 0.3176 | 0.7631 | 0.3555 | 0.7859 | 0.4398 | 0.7912 | 0.4712 |
| MGP-MS | 0.4813 | |||||||||